Developing Engineered Nano-Immunopotentiators for the Stimulation of Dendritic Cells and Inhibition and Prevention of Melanoma

被引:4
作者
Alharthi, Sitah [1 ]
Alavi, Seyed Zeinab [2 ]
Nisa, Mehr un [3 ]
Koohi, Maedeh [2 ]
Raza, Aun [4 ]
Shahmabadi, Hasan Ebrahimi [2 ]
Alavi, Seyed Ebrahim [2 ]
机构
[1] Shaqra Univ, Coll Pharm, Dept Pharmaceut Sci, Al Dawadmi Campus, Al Dawadmi 11961, Saudi Arabia
[2] Rafsanjan Univ Med Sci, Res Inst Basic Med Sci, Immunol Infect Dis Res Ctr, Rafsanjan 7718175911, Iran
[3] Nishtar Med Univ & Hosp, Multan 60000, Pakistan
[4] Fudan Univ, Sch Pharm, Shanghai 201203, Peoples R China
关键词
BRAF-mutant melanoma; cancer; nanoparticles; PEG-PLGA; vaccines; MESOPOROUS SILICA NANOPARTICLES; IN-VIVO EVALUATION; DELIVERY-SYSTEMS; SENSITIVE METHOD; IMIQUIMOD; CANCER; VITRO; OPPORTUNITIES; QUANTITIES; PEGYLATION;
D O I
10.1007/s11095-024-03722-1
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Objective This study aims to utilize PEGylated poly (lactic-co-glycolic acid) (PLGA) nanoparticles as a delivery system for simultaneous administration of the BRAF(V600E) peptide, a tumor-specific antigen, and imiquimod (IMQ). The objective is to stimulate dendritic cell (DC) maturation, activate macrophages, and facilitate antigen presentation in C57BL6 mice. Methods PEG-PLGA-IMQ-BRAF(V600E) nanoparticles were synthesized using a PLGA-PEG-PLGA tri-block copolymer, BRAF(V600E), and IMQ. Characterization included size measurement and drug release profiling. Efficacy was assessed in inhibiting BPD6 melanoma cell growth and activating immature bone marrow DCs, T cells, macrophages, and splenocyte cells through MTT and ELISA assays. In vivo, therapeutic and immunogenic effects potential was evaluated, comparing it to IMQ + BRAF(V600E) and PLGA-IMQ-BRAF(V600E) nanoparticles in inhibiting subcutaneous BPD6 tumor growth. Results The results highlight the successful synthesis of PEG-PLGA-IMQ-BRAF(V600E) nanoparticles (203 +/- 11.1 nm), releasing 73.4% and 63.2% of IMQ and BARF(V600E), respectively, within the initial 48 h. In vitro, these nanoparticles demonstrated a 1.3-fold increase in potency against BPD6 cells, achieving similar to 2.8-fold enhanced cytotoxicity compared to PLGA-IMQ-BRAF(V600E). Moreover, PEG-PLGA-IMQ-BRAF(V600E) exhibited a 1.3-fold increase in potency for enhancing IMQ cytotoxic effects and a 1.1- to similar to 2.4-fold increase in activating DCs, T cells, macrophages, and splenocyte cells compared to IMQ-BRAF(V600E) and PLGA-IMQ-BRAF(V600E). In vivo, PEG-PLGA-IMQ-BRAF(V600E) displayed a 1.3- to 7.5-fold increase in potency for inhibiting subcutaneous BPD6 tumor growth compared to the other formulations. Conclusions The findings suggest that PEG-PLGA nanoparticles effectively promote DC maturation, T cell activation, and potentially macrophage activation. The study highlights the promising role of this nanocomposite in vaccine development.
引用
收藏
页码:1163 / 1181
页数:19
相关论文
共 85 条
[1]   Dual drug delivery of trapoxin A and methotrexate from biocompatible PLGA-PEG polymeric nanoparticles enhanced antitumor activity in breast cancer cell line [J].
Akbari, Elahe ;
Mousazadeh, Hanieh ;
Sabet, Ziba ;
Fattahi, Tannaz ;
Dehnad, Alireza ;
Akbarzadeh, Abolfazl ;
Alizadeh, Effat .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2021, 61
[2]   Bioresponsive nanotechnology in pediatric dental drug delivery [J].
Alavi, Seyed Ebrahim ;
Malik, Lieba ;
Matti, Raghad ;
Al-Najafi, Farah ;
Shahmabadi, Hasan Ebrahimi ;
Sharma, Lavanya A. .
JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY, 2024, 93
[3]   Microfluidics for personalized drug delivery [J].
Alavi, Seyed Ebrahim ;
Alharthi, Sitah ;
Alavi, Seyedeh Fatemeh ;
Alavi, Seyed Zeinab ;
Zahra, Gull E. ;
Raza, Aun ;
Shahmabadi, Hasan Ebrahimi .
DRUG DISCOVERY TODAY, 2024, 29 (04)
[4]   Revolutionizing Wound Healing: Exploring Scarless Solutions through Drug Delivery Innovations [J].
Alavi, Seyed Ebrahim ;
Alavi, Seyed Zeinab ;
Nisa, Mehr Un ;
Koohi, Maedeh ;
Raza, Aun ;
Shahmabadi, Hasan Ebrahimi .
MOLECULAR PHARMACEUTICS, 2024, 21 (03) :1056-1076
[5]   Bioresponsive drug delivery systems [J].
Alavi, Seyed Ebrahim ;
Alharthi, Sitah ;
Alavi, Seyed Zeinab ;
Raza, Aun ;
Shahmabadi, Hasan Ebrahimi .
DRUG DISCOVERY TODAY, 2024, 29 (01)
[6]   Biocomposite-based strategies for dental bone regeneration [J].
Alavi, Seyed Ebrahim ;
Alavi, Seyed Zeinab ;
Gholami, Max ;
Sharma, Ajay ;
Sharma, Lavanya A. ;
Shahmabadi, Hasan Ebrahimi .
ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY, 2023, 136 (05) :554-568
[7]   Hydrogel-based therapeutic coatings for dental implants [J].
Alavi, Seyed Ebrahim ;
Panah, Naomi ;
Page, Franck ;
Gholami, Max ;
Dastfal, Alireza ;
Sharma, Lavanya A. ;
Shahmabadi, Hasan Ebrahimi .
EUROPEAN POLYMER JOURNAL, 2022, 181
[8]   A PEGylated Nanostructured Lipid Carrier for Enhanced Oral Delivery of Antibiotics [J].
Alavi, Seyed Ebrahim ;
Bakht, Urooj ;
Esfahani, Maedeh Koohi Moftakhari ;
Adelnia, Hossein ;
Abdollahi, Seyed Hossein ;
Shahmabadi, Hasan Ebrahimi ;
Raza, Aun .
PHARMACEUTICS, 2022, 14 (08)
[9]   Carboplatin Niosomal Nanoplatform for Potentiated Chemotherapy [J].
Alavi, Seyed Ebrahim ;
Raza, Aun ;
Esfahani, Maedeh Koohi Moftakhari ;
Akbarzadeh, Azim ;
Abdollahi, Seyed Hossein ;
Shahmabadi, Hasan Ebrahimi .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 111 (11) :3029-3037
[10]   PEG-grafted liposomes for enhanced antibacterial and antibiotic activities: An in vivo study [J].
Alavi, Seyed Ebrahim ;
Esfahani, Maedeh Koohi Moftakhari ;
Raza, Aun ;
Adelnia, Hossein ;
Shahmabadi, Hasan Ebrahimi .
NANOIMPACT, 2022, 25